Acuta Capital Partners

Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.

Ocular Therapeutix develops and commercializes ophthalmic therapeutic products by using hydrogel technology.

Tourmaline Bio is a clinical biotechnology company developing transformative medicines to dramatically improve and prevent immune diseases.

Taysha Gene Therapies develops treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system.

BioAtla develops safer, more effective drugs for cancer using a proprietary next-generation antibody discovery and evolution platform.

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.